logo-loader
OTCMKTS:CYDY

CytoDyn

Receive alerts
Market:
OTCMKTS
Market Cap:
$157.53 m
Price
$0.43
Change
1.86%
52 weeks high
0.71
52 weeks low
0.06

Viewing results 1-25 of 70

Health

CytoDyn reports positive results from dose escalating trial with lead drug leronlimab as a HIV monotherapy

The viral load suppression rate after 10 weeks was 68%, 94% and 85% respectively for patients on a 350 mg, 525 mg, and 700 mg drug dose regimen ...

2 days, 20 hours ago
Health

CytoDyn files Phase 2 protocol with FDA for use of leronlimab and regorafenib as combo therapy for metastatic colorectal cancer

The 30-patient study is designed to test the hypothesis that a combination of injected leronlimab and regorafenib taken orally will increase progression-free survival in patients with CCR5-positive metastatic colorectal cancer...

1 week, 2 days ago
Health

CytoDyn marks major milestone for its leronlimab drug with first step into field of cancer

A first patient is being treated under emergency investigational new drug regulations of the US Food and Drug Administration...

1 week, 4 days ago
Micro caps

NA Proactive news snapshot: GSRX Industries, Energy Fuels, CytoDyn, VR Resources …

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires...

1 week, 5 days ago
Health

FDA waives application fees for CytoDyn's BLA filing for HIV drug Leronlimab

CEO Nader Pourhassan says the company's goal is to complete the BLA filing in September for leronlimab as a combination therapy with HAART for HIV-infected patients ...

1 week, 5 days ago
Health

CytoDyn successfully completes preclinical colon cancer treatment studies

The studies found that leronlimab was able to suppress colon carcinoma tumor growth in mice genetically modified to have a human immune system...

2 weeks, 1 day ago
Health

CytoDyn inks exclusive licensing pact with IncellDX to supply non-commercial grade PRO 140 antibody

CEO Nader Pourhassan says the agreement marks an ‘important milestone’ as it puts CytoDyn firmly on pace to generate its first revenue over the next several months...

3 weeks, 1 day ago
Health

CytoDyn finalizes key test which will guide discussions with FDA on lead drug leronlimab as a monotherapy

The company said a face-to-face meeting with the FDA has been granted to discuss a 'pivotal' monotherapy trial...

3 weeks, 2 days ago
Health

CytoDyn taps top AIDS research expert Jonah Sacha as senior science advisor

Dr Sacha will explore the company’s flagship leronlimab drug as a potential therapy for HIV pre-exposure prophylaxis and HIV cure...

on 07/08/2019
Health

CytoDyn eyes revenue in August from deal to supply IncellDX with its non-commercial grade PRO 140

CEO Nader Pourhassan says the deal, likely to be finalized in July, may lead to the company’s first ever product revenue...

on 07/01/2019
Health

CytoDyn to meet with FDA on August 28 to discuss clearance of prostate cancer-detection test

The ProstaGene Prognostic Test is intended for use in patients who have undergone a prostate biopsy and been found to have prostate cancer...

on 06/24/2019
Health

CytoDyn requests FDA meeting to discuss clearance of prostate cancer-detection test

The ProstaGene Prognostic Test is intended for use in patients who have undergone a prostate biopsy and been found to have prostate cancer...

on 06/19/2019
Health

Breakthrough test predicts which HIV patients will respond to CytoDyn's leronlimab as a monotherapy

IncellDx CEO Bruce Patterson says his company is excited to partner with CytoDyn to help bring leronlimab to ‘the right patients at the right time’...

on 06/18/2019
Health

Thai Red Cross AIDS Research Centre to conduct a pre-exposure prophylaxis clinical HIV trial of CytoDyn’s leronlimab

The Thai trial’s results could potentially be used for label extension of leronlimab in other jurisdictions, including the FDA...

on 06/17/2019